Search results for "Drug resistance"

showing 10 items of 953 documents

BYOTYPES AND RANDOMLY AMPLIFIED POLYMORPHIC DNA (RAPD) PROFILES OF SUBGINGIVAL CANDIDA ALBICANS ISOLATES IN HIV INFECTION

2005

ABSTRACT: A group of subgingival isolates of C. albicans recovered from Italian HIV-positive (HIV+) subjects were characterized both phenotypically and genotypically. Phenotyping of the isolates was carried out by a biotyping method based on the enzyme profiles, carbohydrate assimilation patterns and boric acid resistance of the yeasts. Genotyping was performed through randomly amplified polymorphic DNA (RAPD) analysis. Five biotypes were found among the 29 subgingival C. albicans strains examined. The predominant biotypes were A1R (55.17%), A1S (24.14%), and A2R (13.79%), while the biotypes A11R and A13R were represented by a single isolate each. RAPD profiles identified 15 genotypes among…

AdultMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaAntifungal AgentsAIDS-Related Opportunistic InfectionsGenotypeSettore MED/42 - Igiene Generale E ApplicataDNA FingerprintingRandom Amplified Polymorphic DNA TechniquePhenotypeCandida albicans HIV-positiveBoric AcidsItalySettore MED/28 - Malattie OdontostomatologicheCandidiasis OralDrug Resistance FungalCandida albicansGingival DiseasesHumansFemaleDNA FungalMycological Typing Techniques
researchProduct

Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B…

2009

Background The high degree of diversity of the hepatitis B virus (HBV) quasispecies in chronically infected individuals raises the possibility that HBV genetic variants favouring resistance to nucleoside/nucleotide analogues (NAs) might pre-exist to treatment. The aim of this study was to investigate the genetic variability of the entire HBV reverse transcriptase (RT) domain and of the overlapping S gene in a large series of untreated hepatitis B surface antigen carriers and in lamivudine (3TC)-resistant patients. Methods Sequencing analysis of the entire HBV RT domain of isolates from 100 untreated (treatment- naive group) and 59 3TC-resistant (3TC-resistant group) consecutive patients wit…

AdultMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaHepatitis B virusAdult; Aged; Drug Resistance; Viral; Female; Genetic Variation; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B; Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Reverse Transcriptase Inhibitors; Sequence Analysis; DNA; Treatment OutcomeDrug ResistanceViral quasispeciesmedicine.disease_causeVirusHepatitis B ChronicOrthohepadnavirusDrug Resistance ViralmedicineHumansPharmacology (medical)ViralChronicAgedPharmacologyHepatitis B virusSettore MED/12 - GastroenterologiaHepatitis B Surface AntigensbiologyReverse-transcriptase inhibitorLamivudineGenetic VariationRNA-Directed DNA PolymeraseSequence Analysis DNADNAMiddle Agedbiology.organism_classificationHepatitis BVirologyReverse transcriptaseInfectious DiseasesTreatment OutcomeHepadnaviridaeLamivudineMutationReverse Transcriptase InhibitorsHBV reverse transcriptase gene S lamivudine resistantFemaleSequence Analysismedicine.drug
researchProduct

Molecular epidemiology of tuberculosis in Sicily, Italy: what has changed after a decade?

2014

Background We aimed to investigate the molecular epidemiology of Mycobacterium tuberculosis complex (MTBC) isolates in the province of Palermo, Sicily, Italy, by characterizing 183 isolates identified in the years 2004-2012. A comparison with 104 MTBC strains identified in the same geographic area in the years 1994-2000 was also carried out. Methods One hundred eighty-three MTBC isolates identified in Palermo, Italy, in the years 2004-2012 were analyzed by spoligotyping and the 24 mycobacterial interspersed repetitive unit (MIRU)-variable-number tandem-repeat (VNTR) method typing. Susceptibility testing to streptomycin, isoniazid, rifampin and ethambutol was also performed. Furthermore, the…

AdultMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaVeterinary medicineTuberculosis Sicily Epidemiology Spoligotyping MIRU-VNTRTuberculosisGenotypeEpidemiologyLineage (evolution)Microbial Sensitivity TestsMinisatellite RepeatsSettore MED/42 - Igiene Generale E ApplicataMIRU-VNTRDrug Resistance BacterialIsoniazidMedicineTuberculosisHumansTypingSicilyAntibiotics AntitubercularEthambutolSpoligotypingMolecular EpidemiologyMolecular epidemiologybiologybusiness.industryMycobacterium tuberculosisMiddle Agedmedicine.diseasebiology.organism_classificationMolecular TypingInfectious DiseasesParasitologyMycobacterium tuberculosis complexStreptomycinFemaleRifampinbusinessEthambutolmedicine.drugResearch ArticleBMC Infectious Diseases
researchProduct

Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma.

2020

CD4 T cells play a key role in anticancer immunity. In this study, we investigate the clinical relevance of circulating CD4 T helper type 1 (Th1) response against telomerase (anti-TERT Th1 response) in patients with melanoma. The spontaneous anti-TERT Th1 response was detected in 54.5% (85/156) of patients with melanoma before treatment. The prevalence of this systemic response was inversely related to Breslow thickness >1 mm and American Joint Committee on Cancer stage ≥II (P = 0.001 and 0.032, respectively). In contrast to patients treated with targeted therapies, the anti-TERT Th1 immunity was associated with an objective response after immune checkpoint inhibitors treatment. Hence, 86% …

AdultMaleTelomeraseSkin Neoplasmsmedicine.medical_treatmentDermatologyBiochemistryBreslow ThicknessImmunitymedicineHumansTelomerase reverse transcriptaseProgression-free survivalProspective StudiesMolecular BiologyImmune Checkpoint InhibitorsMelanomaTelomeraseAgedNeoplasm Stagingbusiness.industryMelanomaCell BiologyImmunotherapyMiddle AgedTh1 Cellsmedicine.diseaseProgression-Free SurvivalDrug Resistance NeoplasmCancer researchBiomarker (medicine)FemalebusinessFollow-Up StudiesThe Journal of investigative dermatology
researchProduct

Clinical impact of broad-spectrum empirical antibiotic therapy in patients with healthcare-associated pneumonia: a multicenter interventional study

2012

Healthcare-associated pneumonia (HCAP) has been proposed as a new category of pneumonia distinct from community-acquired pneumonia (CAP). A multicenter observational study in 2008 finds that patients with HCAP have a mortality rate significantly higher than patients with CAP, and a worse outcome is associated at logistic regression analysis with a low adherence to empirical antibiotic therapy recommended by ATS/IDSA guidelines. We designed a prospective interventional study to establish whether administration of a broad-spectrum antibiotic therapy consistent with the 2005 ATS/IDSA guidelines has an effect on the clinical outcome of hospitalized patients with HCAP. All patients with HCAP pro…

AdultMalecommunity-acquired pneumonia; broad-spectrum empirical therapy; healthcare-associated pneumonia; multidrug-resistant pathogens; antibiotic therapymedicine.medical_specialtyCarbapenemcommunity-acquired pneumoniaSettore MED/09 - Medicina InternaAdolescentLogistic regressionNOYoung AdultCommunity-acquired pneumoniaDrug Resistance Multiple BacterialInternal medicinePneumonia BacterialInternal Medicinemedicineantibiotic therapyHumanspneumoniaProspective StudiesYoung adultIntensive care medicineProspective cohort studyAgedAged 80 and overCross Infectionbusiness.industryMortality ratehealthcare-associated pneumoniaHealthcare-associated pneumonia Community-acquired pneumonia Antibiotic therapy Multidrug-resistant pathogens Broad-spectrum empirical therapybroad-spectrum empirical therapyLength of StayMiddle Agedmedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheAnti-Bacterial AgentsPneumoniamultidrug-resistant pathogensItalyPractice Guidelines as TopicEmergency MedicineDrug Therapy CombinationFemaleObservational studybusinessantibiotic therapy; pneumoniamedicine.drug
researchProduct

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive …

2012

Background: The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission. While compensatory mutations increase fitness during treatment, their presence may also modulate viral fitness and virulence in absence of therapy and major resistance mutations. We previously designed a modeling technique that quantifies genotypic footprints of in vivo treatment selective pressure, including both drug …

AdultMalelcsh:Immunologic diseases. AllergyAnti-HIV AgentseducationVirulenceHIV InfectionsDrug resistanceBiologySettore MED/42 - Igiene Generale E ApplicataViruspolymorphism03 medical and health sciencesViral ProteinsSDG 3 - Good Health and Well-beingVirologyGenotypeDrug Resistance Viraldrug-naivemedicineHumansProspective Studies030304 developmental biology0303 health sciencesPolymorphism Genetic030306 microbiologyResearchproteaseViral LoadVirologyReverse transcriptase3. Good healthCD4 Lymphocyte CountDrug-naïveInfectious Diseases3121 General medicine internal medicine and other clinical medicineImmunologybiology.proteinHIV-1FemaleAntibodylcsh:RC581-607Viral loadHIV-1 infected patientmedicine.drugPeptide HydrolasesRetrovirology
researchProduct

Zygomycosis in Italy: A survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology)

2009

Abstract The aims of the study were to analyze the clinical and epidemiological characteristics and treatments for patients who developed zygomycosis enrolled in Italy during the European Confederation of Medical Mycology of medical mycology survey. This prospective multicenter study was performed between 2004 and 2007 at 49 italian Departments. 60 cases of zygomycosis were enrolled: the median age was 59.5 years (range 1-87), with a prevalence of males (70%). The majority of cases were immunocompromised patients (42 cases, 70%), mainly hematological malignancies (37). Among non-immunocompromised (18 cases, 30%), the main category was represented by patients with penetrating trauma (7/18, 3…

AdultMalemedicine.medical_specialtyAdolescentEpidemiologyAntifungal drugImmunocompromised HostPharmacotherapyZygomycosisDrug Resistance FungalAmphotericin BInternal medicineEpidemiologymedicineHumansPharmacology (medical)ChildMycosisAgedPharmacologyImmunocompromised hostAged 80 and overbusiness.industryMortality rateMucormycosisInfantEpidemiology; Immunocompromised host; ZygomycosisMiddle Agedmedicine.diseaseSurgeryInfectious DiseasesOncologyItalyChild PreschoolFemaleZygomycosisbusinessmedicine.drug
researchProduct

Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled …

2016

Background Chronic spontaneous urticaria (CSU) severely impacts quality of life (QoL), especially in patients with wheals and angioedema. Omalizumab is approved as add-on therapy for CSU patients; however, its effect on patients who are double-positive for wheals and angioedema has not been systematically studied. Objective The primary objective was to evaluate the efficacy of omalizumab vs placebo at week 28 using the Chronic Urticaria Quality of Life (CU-Q2oL) questionnaire. Number of angioedema-burdened days, time interval between successive angioedema episodes, disease activity, angioedema-specific and overall QoL impairment were secondary objectives. Methods X-ACT was a phase III, rand…

AdultMalemedicine.medical_specialtyAdolescentUrticariamedicine.medical_treatmentImmunologyDrug ResistanceOmalizumabOmalizumabPlacebolaw.inventionYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled trialQuality of lifeimmune system diseaseslawInternal medicineAnti-Allergic AgentsmedicineHumansImmunology and AllergyAngioedemaYoung adultskin and connective tissue diseasesAdverse effectAgedAngioedemabusiness.industryMiddle AgedTreatment Outcome030228 respiratory systemAnesthesiaChronic DiseaseRetreatmentHistamine H1 AntagonistsQuality of LifeFemaleAntihistaminemedicine.symptombusinessmedicine.drugAllergy
researchProduct

Transmission of Drug-Resistant HIV Type 1 Strains in HAART-Naive Patients: A 5-Year Retrospective Study in Sicily, Italy

2010

The transmission of drug-resistant HIV-1 strains might compromise the efficacy of current first-line antiretroviral (ARV) regimens. Between 2004 and 2008, HIV-1 reverse transcriptase (RT) and protease (PR) genes of 108 ARVnaive Sicilian patients were amplified and sequenced to describe the prevalence of ARV resistance mutations among HAART-naive HIV-1-infected individuals. The frequency of transmitted drug resistance mutations (DRAMs) was determined by using genotypic interpretation algorithms. The proportion of HAART-naive HIV- 1-infected patients in Sicily increased from 18.4% to 23.5% during 2004–2008. Among naive patients, the overall prevalence of DRAMs was 15.7% [17/108; 95% CI: 9.4–2…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentMolecular Sequence DataImmunologyHIV InfectionsDrug resistanceSettore MED/42 - Igiene Generale E ApplicataVirusYoung AdultAntiretroviral Therapy Highly ActiveVirologyMolecular geneticsDrug Resistance ViralGenotypePrevalencemedicineHumansChildSicilyAgedRetrospective StudiesHAART-naive HIV-1 drug resistanceProteaseMolecular epidemiologybiologyInfantvirus diseasesHIV Protease InhibitorsMiddle Agedbiology.organism_classificationVirologyReverse transcriptaseInfectious DiseasesChild PreschoolMutationLentivirusHIV-1Reverse Transcriptase InhibitorsFemaleAIDS Research and Human Retroviruses
researchProduct

Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe

2013

Objective Scanty information is available on the clinical characteristics of resistant hypertension in Central and East European countries. The Blood Pressure (BP) control rate and CArdiovascular Risk profilE (BP-CARE) study allowed us to assess the prevalence and the main clinical features of resistant hypertension in this population. Design and method The study was carried out in 1312 treated hypertensive patients living in nine Central and East European countries. Results Four hundred and twenty-three patients had apparent resistant hypertension, of whom 168 had pseudo-resistant hypertension (noncompliant/white-coat) and 255 were true treatment-resistant hypertension patients (TRH). Clin…

AdultMalemedicine.medical_specialtyAmbulatory blood pressurePhysiologyCross-sectional studyPopulationDrug ResistanceRenal functionBlood PressureBody Mass IndexRisk FactorsInternal medicinePrevalenceInternal MedicinemedicineHumansEurope EasternObesityRenal InsufficiencyeducationAntihypertensive AgentsAgededucation.field_of_studybusiness.industryresistant hypertensionBlood Pressure DeterminationMiddle Agedmedicine.diseaseObesityCross-Sectional StudiesTreatment OutcomeEndocrinologyBlood pressureCardiovascular DiseasesHeart failureHypertensionFemaleCardiology and Cardiovascular MedicinebusinessBody mass indexWhite Coat HypertensionGlomerular Filtration RateJournal of Hypertension
researchProduct